Publications by authors named "L B GALLAGHER"
Background: Dental treatment may not be possible for patients with a profound acquired brain injury without pharmacological support. Intravenous (IV) sedation with midazolam is a widely accepted, safe, and effective mode of treatment for people with a disability, but there is limited evidence in this patient cohort.
Aims: This evaluation aimed to review the IV sedation service for patients with profound acquired brain injury within the dental department at the Royal Hospital for Neuro-disability.
Beyond genomics in Patescibacteria: A trove of unexplored biology packed into ultrasmall bacteria.
Proc Natl Acad Sci U S A
December 2024
Article Synopsis
- Patescibacteria, or Candidate Phyla Radiation, is a diverse group of mostly uncultivated small bacteria that accounts for a large part of bacterial diversity.
- Some cultivated members show a unique life cycle as obligate epibionts, meaning they live on the surface of host bacteria.
- Recent advances in studying these organisms have led to breakthroughs in understanding their metabolic functions and developing strategies for cultivation, which could help reveal the complex interactions between Patescibacteria and their hosts.
Introduction: Advancing research and support for neurologically diverse populations requires novel data harmonisation methods that are capable of aligning with contemporary approaches to understanding health and disability.
Objectives: We present the International Classification of Functioning, Disability and Health (ICF) as a conceptual framework to support harmonisation of mental health data and present a proof of principle within the Risk and Resilience in Developmental Diversity and Mental Health (R2D2-MH) consortium.
Method: 138 measures from various mental health datasets were linked to the ICF following the WHO's established linking rules.
Article Synopsis
- - PARP inhibitors show promise in treating castration-resistant prostate cancer (CRPC) with homologous recombination repair (HRR) defects, but the reasons behind resistance are not completely understood.
- - A study from the TOPARP-B trial found that 79% of BRCA2/PALB2-mutated tumors exhibited reversion mutations at the end of treatment, with many related to POLQ-mediated DNA repair mechanisms.
- - In cases of BRCA2 homozygous deletions, rare subclones lacking the BRCA2 deletion are selected for after PARP inhibitor treatment, indicating the necessity for restored HRR function in developing resistance.